And-1 (PD-1/L1). The median age was 60 years (Table 1). ICPI treatment discontinuation was because of IMD in 76 sufferers (66). Seventy-nine individuals (68) expected immunosuppressive therapy for the first occasion of IMD. The median duration from the last ICPI dose towards the restart of ICPI therapy was 65 days (SD, 194). All round, 37 (32) sufferers seasoned a recurrence of IMD (CTLA-4, 48 ; PD-1/L1, 28). Twenty-seven sufferers (73) expected immunosuppression for the recurrent IMD (Table two); 15 of them discontinued ICPI therapy. The median duration from ICPI reinitiation to IMD recurrence was 63 days (variety, 197). Severe IMD requiring immunosuppression initially was connected with greater grades (P0.001) and much more frequent immunosuppression requirement (P0.001; Table three) for the recurrent IMD. On multivariate logistic regression, sufferers who received anti-CTLA-4 primarily based therapy initially had lower threat of IMD recurrence (odds ratio [OR], 0.20, 95 CI, 0.08-0.51; P=0.001; Table 4-5). The requirement for immunosuppression for IMD initially (OR, 3.04; 95 CI, 1.12-8.29; P=0.030) and the resumption of anti-CTLA-4 agents (OR, three.89; 95 CI, 1.22-12.40; P=0.022) have been associated with enhanced threat of IMD recurrence. Conclusions The resumption of anti-PD-1/L1 therapy has a reduce IMD recurrence price when compared with anti-CTLA-4. Therefore, ICPI therapy, specifically anti-PD1-PD-L1, may perhaps be resumed as a way to maximize the clinical advantage for sufferers who’ve restricted option remedy choices. Extreme IMD requiring immunosuppression initially was a threat issue for the recurrence of severe IMD after ICPI resumption.References 1. Pollack, MH, et al., Security of resuming anti-PD-1 in sufferers with immunerelated adverse events (irAEs) throughout combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol, 2018. 29(1): 250-255.Ethics Approval This Testicular Receptor 2 Proteins Biological Activity retrospective, single-center study was authorized by the Institutional Assessment Board in the University of Texas MD Anderson Cancer Center (IRB No. PA18-0472). Consent This study was granted waiver for consent.Table 1 (Endothelial Cell-Selective Adhesion Molecule (ESAM) Proteins Molecular Weight abstract P536). Basic characteristics in the initial colitis eventJournal for ImmunoTherapy of Cancer 2018, 6(Suppl 1):Web page 284 ofTable two (abstract P536). Qualities from the recurrent immunemediated diarrhea depending on the ICPI therapy resumedTable three (abstract P536). Traits with the recurrent immunemediated diarrhea for individuals who required immunosuppression for the initial immune-mediated diarrheaFig. 1 (abstract P536). The recurrence rate of immune-mediated diarrhea (IMD) following ICPI resumption according to the immunosuppression (IS) requirement for the initial immune-mediated diarrheaTable 4 (abstract P536). Univariate logistic regression analysis of immune-mediated diarrhea recurrenceFig. two (abstract P536). The reccurence immune-mediated diarrhea immediately after ICPI resumption by the kind of ICPIP537 Immune checkpoint inhibitor nduced colitis as a predictor of survival in metastatic melanoma Hamzah Abu-Sbeih, MD, Faisal S. Ali, Wei Qiao, PhD, Yang Lu, MD, Sapna Patel, MD, Adi Diab, MD, Yinghong Wang, MD, PhD MD Anderson Cancer Center, Houston, TX, USA Correspondence: Yinghong Wang ([email protected]) Journal for ImmunoTherapy of Cancer 2018, six(Suppl 1):P537 Background Gastrointestinal (GI) immune connected adverse events (irAEs) normally limit immune checkpoint inhibitors’ (ICPIs) treatment, which is extremely effective for metastatic melanoma. The influence of GI-irAEs and their immunosuppressive therapy on patie.